Founded in 1992 and headquartered in Northern California, Conceptus (CPTS) is engaged in the design, development, promotion and distribution of innovative medical products for use in the field of women's health.

Conceptus believes this technology is transforming the field of permanent birth control, and is currently focused on marketing Essure permanent birth control worldwide.

In 2002, the U.S. Food and Drug Administration granted approval to market the Essure device in the United States, a market where over 700,000 tubal ligations and 400,000 vasectomies are performed annually.

The Essure system is approved for sale in many countries and regions, including the United States, Europe, Canada, Mexico, Australia, New Zealand, Singapore, Central and South America. Conceptus continues efforts to make the Essure system available world-wide by applying for appropriate regulatory and/or governmental clearances.

The Essure procedure is a non-incisional alternative to surgical tubal ligation, the leading form of birth control worldwide. While tubal ligation involves abdominal incisions, general anesthesia, four to five days of recovery time, and the risks associated with surgery. The Essure procedure does not require cutting or penetrating the abdomen. The procedure can be performed in an outpatient setting without general anesthesia, and women who have the procedure usually resume regular activities within 24-48 hours after the day of the procedure.